Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid vs risedronate after vertebroplasty to prevent subsequent vertebral compression fractures
KCT0003919Phase 4Not yet recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of zoledronic acid, risedronate in vertebral compression fracture (VCF), sponsored by Daewoong Pharmaceutical. Planned start May 2019; status: not yet recruiting.
02
Drugs
zoledronic acidrisedronate
03
Conditions
vertebral compression fracture (VCF)
Beyond the preview
Go deeper on KCT0003919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003919.